Fibrin extravasating into Bowman's capsule in this case of MPO-ANCA associated pauci immune GN. Destructive necrotizing cellular crescent. Prominent necrotizing arteritis as well. #renalpath #pathsky #nephsky
Sarah Sanghavi
@sarahsanghavi.bsky.social
Intensivist, Nephrologist @uwnephrology.bsky.social | Via UT Austin, UTSW, WashU, and Mt. Sinai | Views mine https://nephrology.uw.edu/people/faculty/sanghavi-s #nephsky #medsky
Huge step in the right direction. Serological anti-NELL1 antibodies are necessary to improve the diagnosis and management of NELL1-membranous nephropathy #NephSky
Kidney International@kidneyint.bsky.social · last wk.Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy doi.org/10.1016/j.kint.2026.05.017 #MedSky #NephSky #OpenAccess #membranousnephropathy #nephroticsyndrome
Haven't seen one of these in a while. Example of atheroembolism in a older pt with subacute kidney injury and peripheral vascular disease. Cholesterol clefts and giant cells filling the arterial lumen. #renalpath #pathsky #nephsky
Thank you to our outstanding #Nephrology #Fellowship leaders, Dr. Fionnuala Cormack (left), Danielle Long (2nd from left), and Dr. Cary Paine (right), with our 2026 graduates Drs. Lily Jeong, Liz Kiernan, Sarah Haeger, Bang Zheng, Dale Braimah, and Josh Earl. @uwdeptmedicine.bsky.social #kidney
Combined anti-CD20/anti-CD38 therapy in recurrent FSGS: Results Before Reasons - Kidney International Reports www.kireports.org/article/S246...
Combined anti-CD20/anti-CD38 therapy in recurrent FSGS: Results Before Reasons
Recurrent focal segmental glomerulosclerosis (rFSGS) remains one of the most feared complications after kidney transplantation. Recurrence occurs in approximately one-third of patients with primary FS...
kireports.org
“How much is a magical world worth?” A beautiful thread about Cabo Verde, the Peace Corps, and the World Cup:
Took us more than 10 years to get this to this stage AVF versus catheters - doing an RCT was difficult and we learnt a lot. Hope our community also does?
Comparing Catheters to Fistulas in Older Patients Starting... : Journal of the American Society of Nephrology
recommendations were based is observational with potential for bias. Methods A pilot randomized controlled trial was conducted in 12 hemodialysis centers in Canada and Australia. Individuals aged 55…
journals.lww.com
Teacher of the Year! Congratulations to Dr. Cary Paine on being selected as our AY2025-26 UW Nephrology Teacher of the Year!! Fellows announce the award annually at our end-of-year graduation celebration dinner. @uwmedicine.bsky.social #nephsky #meded #nephrology #kidney #teacher
PREVENT-CVD better predicts combined cardio-kidney outcomes in CKD than traditional risk scores, according to #ASNCJASN study. Adding albuminuria boosts performance, highlighting its value for integrated cardio-renal risk assessment. https://twp.ai/9OW0ka
Dr. Kate Butler gives a fantastic presentation, followed by a dynamic group discussion: "Should adherence be a requirement for kidney transplant candidates?" #nephsky #kidney #transplant #nephrology @uwmedicine.bsky.social youtu.be/f6mYNOetgDE
Catherine Butler, MD, MA - Should Adherence Be A Requirement For Kidney Transplant Candidates?
YouTube video by University of Washington Division of Nephrology
youtu.be
Congratulations to the 2026 recipients of our Chair of Medicine Scholars Awards!! ⭐Dr. Sally Baker, @uwidfellowship.bsky.social ⭐Dr. Megan Capozzi, Metabolism, Endocrinology & Nutrition ⭐Dr. Michael Grandaz, @uwnephrology.bsky.social ⭐Dr. Sarah Holton, Pulmonary, Critical Care and Sleep Medicine
Tirzepatide slowed the rate of GFR decline more than dulaglutide in higher risk CKD. Interestingly, there were more GI side effects- haven’t seen that in practice.
David W (aka Flex NP)@rnflex.bsky.social · 3mo agoI have been WAITING for this exploratory analysis of renal outcomes from SURPASS CVOT! Long story short, no matter how you dice it tirzepatide significantly helps, even more so in severe CKD. #NephSky @mikejohansenmd.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social
Agree with this All formulae for corrected calcium are imperfect Just measure ionized calcium pubmed.ncbi.nlm.nih.gov/42035248/ #EMIMCC
Albumin-adjusted ("corrected") calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD - PubMed
Albumin-adjusted ("corrected") calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD
pubmed.ncbi.nlm.nih.gov
"In the era of [AI], take-home writing assignments have become so difficult to police for integrity" that many teachers have "stopped assigning them. Instead,...[they're] requiring students to write inside the classroom, where they can be observed." I think... 🧵 www.nytimes.com/2026/04/30/u...
How A.I. Killed Student Writing (and Revived It)
nytimes.com
Plasma exchange for severe alveolar hemorrhage in antineutrophil cytoplasmic antibody–associated vasculitis: emulation of a target trial academic.oup.com/ajrccm/artic... @atscommunity.bsky.social
Ben Riley was already writing about the risks of chatbots when his dad started trusting A.I. over his doctor.
He Warned About the Dangers of A.I. If Only His Father Had Listened.
Ben Riley was already writing about the risks of chatbots when his dad started trusting A.I. over his doctor.
nyti.ms
What a great turnout for our Spring WIN-Women in #Nephrology gathering! Many thanks to Dr. Leah Haseley for hosting & Dr. Laura Mayeda for organizing the event. Shout-out to our amazing fellows and faculty women of UW Nephrology @uwnephrology.bsky.social @uwmedicine.bsky.social #nephsky #kidneydocs
🫀 SPIRIT-HF at #ACC26: Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of HF hospitalizations and cardiovascular death at 24 months in patients with #HFpEF or #HFmrEF. See the results ➡️ https://bit.ly/4cbiPeW #HeartFailure #CardioSky
A KDIGO commentary on B Cell and Complement guided therapy in IgAN www.kidney-international.org/article/S008... in Kidney Int Perfectly timed for #NephMadness (and this will be the champion)
![Figure 1 Therapeutic targets and positioning of treatments in IgA nephropathy (IgAN). Reflecting our latest understanding, treatments should target IgAN-specific drivers for nephron loss (Hits 1-3, Hit 4) and generic response to IgAN-induced nephron loss. Drugs targeting the IgAN-specific drivers for nephron loss likely act on different mechanisms of the 4-hit hypothesis. Triangles denote that a drug class most likely exerts its key actions on either Hits 1-3 or Hit 4 but may target all hits to a variable extent as indicated by their lengths of the triangle. Nefecon, APRIL inhibitors, and dual APRIL-BAFF inhibitors are shown as having a predominant effect on the production of pathogenic forms of IgA and IgA containing immune complexes (IgA-ICs) [Hits 1-3] while systemic glucocorticoids and complement inhibitors are shown as having a predominant anti-inflammatory effect on IgA-IC mediated kidney injury [Hit 4]. Interventions to manage the generic response to IgAN-induced nephron loss include lifestyle modifications, RASi or DEARA use with or without SGLT2i, or use of a DEARA or a combination of ERA and RASi. Additional strategies may also include the use of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in select patients. The drugs listed here do not imply a recommended ranking or delivery sequence. APRIL, a proliferation-inducing ligand; BAFF, B cell–activating factor; DEARA, dual endothelin angiotensin receptor antagonist; ERA, endothelin type A receptor antagonist; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:33h4q6nw674jdcwfxaq2m2nl/bafkreidryzyepbhcxh4g7cjglwmmk6tfgyxmujh55el3ey76ki4zp4qa5i)
We had a great “Battle of the UW Neph Sections" for #NephMadness2026 ! The energy was fantastic as our faculty and fellows jumped into spirited discussions to create a UW #Nephrology bracket 🏆🫘🤩 #kidney #nephsky #meded @uwmedicine.bsky.social
Great shot of our "Team Evergreen" advocates from @uwmedicine.bsky.social!! They will be on #CapitolHill in DC tomorrow to advocate for 1) #Research funding for #kidneycare at NIDDK and 2) Lowering barriers to living #kidneydonation through the ESLDA (Expanding Support for Living Donors Act). 🙌🫘📣
Apixaban wins www.nejm.org/doi/full/10....
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism | NEJM
Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two m...
nejm.org
Here is today’s #eyeSCANdy! Scanning EM of a normal glomerulus showing a glomerular capillary loop with interdigitating podocyte foot processes. Photo courtesy of Dr. Stephen Bonsib. #renal #pathology #kidneypath
Very cool Enteric coated budesonide also reduces albuminuria, and GFR remains stable in #IgAN Single arm prospective study from India in KI Reports www.kireports.org/article/S246...
